• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Vicarious Surgical Announces New Hospital System Partnership with LSU Health New Orleans

    8/7/24 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care
    Get the next $RBOT alert in real time by email

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has signed a strategic development agreement with the LSU Health New Orleans.

    LSU Health New Orleans is Louisiana's flagship and most comprehensive academic health sciences center. Known for the quality of its academic and training programs, the center educates the majority of Louisiana's health care professionals. LSU Health New Orleans partners with University Medical Center (UMC), which hosts the largest medical training center in Louisiana. At the heart of UMC's operations is a network of over 760 physicians, supported by 446 licensed inpatient beds, 369 exam rooms, and 23 state-of-the-art surgical suites. UMC treats more than 200,000 patients annually across primary and specialty care. Across the broader LSU Health New Orleans system, faculty are responsible for more than 1 million patient visits annually.

    Through the agreement, Vicarious Surgical will gain access to the LSU Health New Orleans network and collaborate directly with its team of experienced robotic surgeons and supporting staff. The partnership will leverage LSU Health New Orleans's extensive surgeon training expertise to validate training protocols and identify expected drivers of surgeon adoption. The partnership also offers Vicarious Surgical the opportunity to collaborate on formative studies investigating the clinical and economic value proposition of the Company's V1.0 system. LSU Health New Orleans's profile as a regional care provider with an academic emphasis differentiates the partnership and offers Vicarious Surgical the opportunity to better understand the dynamics driving adoption in these settings.

    "We're thrilled to partner with LSU Health New Orleans as we tailor our system development and commercial launch strategies to meet the needs of individual care networks," said Adam Sachs, CEO and Co-Founder, Vicarious Surgical. "As a regional provider with a prominent academic arm, LSU Health New Orleans offers unique insight into the administrative and clinical protocols associated with regional care centers of a similar profile. At the same time, their emphasis on physician training, involving learners at all levels, represents a meaningful opportunity for our team to collaborate with the next generation of surgeons and gain insight into the drivers of future system adoption."

    "As a network of providers dedicated to educating and mentoring the next generation of healthcare professionals, we are always looking at ways to improve the current standard of care," said Dr. Michael Cook, Associate Professor of Clinical Surgery at LSU Health New Orleans. "Soft-tissue robotic surgery is an area of focus within our organization, and the differentiated value proposition supporting Vicarious' single-port approach represents a meaningful step towards better care for patients. We look forward to working with the entire Vicarious Surgical team to further our joint mission of improving patient lives."

    About Vicarious Surgical

    Founded in 2014, Vicarious Surgical is a next generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.

    About LSU Health New Orleans

    LSU Health New Orleans educates Louisiana's health care professionals. The state's health sciences university leader, LSU Health New Orleans includes a School of Medicine with campuses in New Orleans, Baton Rouge and Lafayette, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSU Health New Orleans faculty take care of patients in hospitals and clinics throughout the region. In the vanguard of biosciences research, the LSU Health New Orleans research enterprise generates jobs and enormous annual economic impact. LSU Health New Orleans faculty have made lifesaving discoveries and continue to work to prevent, advance treatment and cure disease.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240807415785/en/

    Get the next $RBOT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RBOT

    DatePrice TargetRatingAnalyst
    3/4/2022$16.00 → $7.00Overweight → Neutral
    Piper Sandler
    1/7/2022$16.00Outperform
    Credit Suisse
    12/7/2021$15.00Outperform
    Cowen & Co.
    11/5/2021$15.00Buy
    Canaccord Genuity
    10/18/2021$15.00Buy
    BTIG
    10/7/2021$16.00Overweight
    Piper Sandler
    More analyst ratings

    $RBOT
    SEC Filings

    View All

    Vicarious Surgical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Vicarious Surgical Inc. (0001812173) (Filer)

    4/8/26 4:30:07 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Vicarious Surgical Inc.

    SCHEDULE 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)

    4/6/26 7:01:15 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form DEF 14A filed by Vicarious Surgical Inc.

    DEF 14A - Vicarious Surgical Inc. (0001812173) (Filer)

    3/23/26 4:30:03 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair

    WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company's targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar sc

    3/30/26 4:15:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing

    WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced that it has received approval for its Class A common stock to upgrade to the OTCQB® Venture Market by OTC Markets Group Inc. (the "OTCQB"). The Company's Class A common stock has begun quotation on the OTCQB as of March 24, 2026, under the ticker symbol RBOT. This milestone represents a key step in the Company's broader capital markets strategy as it advances toward a potential listing on the Nasdaq Capital Market. The OTCQB is designed for early-stage and developing companies

    3/25/26 4:15:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Receives Delisting Notice From NYSE

    Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con

    3/4/26 7:00:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Sachs Adam David sold $1,967 worth of shares (942 units at $2.09), decreasing direct ownership by 2% to 46,943 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    2/24/26 4:59:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Chief Technology Officer Khalifa Sammy sold $1,571 worth of shares (754 units at $2.08), decreasing direct ownership by 2% to 32,869 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    2/24/26 4:58:35 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    President Sachs Adam David sold $1,367 worth of shares (463 units at $2.95), decreasing direct ownership by 0.96% to 47,885 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    12/4/25 7:14:04 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vicarious Surgical downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Vicarious Surgical from Overweight to Neutral and set a new price target of $7.00 from $16.00 previously

    3/4/22 4:51:18 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Credit Suisse initiated coverage on Vicarious Surgical with a new price target

    Credit Suisse initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $16.00

    1/7/22 7:09:02 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Cowen & Co. initiated coverage on Vicarious Surgical with a new price target

    Cowen & Co. initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $15.00

    12/7/21 7:31:51 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer

    Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h

    3/13/25 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a

    1/29/24 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Financials

    Live finance-specific insights

    View All

    Vicarious Surgical Receives Delisting Notice From NYSE

    Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con

    3/4/26 7:00:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical to Report Third Quarter 2025 Financial Results on November 12, 2025

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will now report financial results for the third quarter ended September 30, 2025 after the market closes on Wednesday, November 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 623856. A live and archived webcast of the event will be available at ht

    11/6/25 6:13:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical to Report Third Quarter 2025 Financial Results on November 13, 2025

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the third quarter ended September 30, 2025 after the market closes on Thursday, November 13, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 623856. A live and archived webcast of the event will be available at https:

    10/30/25 4:05:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

    SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

    2/13/24 4:36:42 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

    SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

    8/15/23 10:28:36 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form SC 13D/A filed by Vicarious Surgical Inc. (Amendment)

    SC 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)

    8/9/23 5:10:57 PM ET
    $RBOT
    Industrial Specialties
    Health Care